<?xml version="1.0" encoding="UTF-8"?><!-- generator="wordpress/2.3.1" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>
<channel>
	<title>Comments on: Immunogen at ASH 2007 – part II (AVE9633)</title>
	<link>http://www.hammerstockblog.com/immunogen-at-ash-2007-%e2%80%93-part-ii-ave9633/</link>
	<description>Biotech stock reviews</description>
	<pubDate>Sat, 13 Mar 2010 17:55:13 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.3.1</generator>
		<item>
		<title>By: Active Traders Network</title>
		<link>http://www.hammerstockblog.com/immunogen-at-ash-2007-%e2%80%93-part-ii-ave9633/#comment-489</link>
		<dc:creator>Active Traders Network</dc:creator>
		<pubDate>Wed, 28 Jan 2009 13:29:51 +0000</pubDate>
		<guid>http://www.hammerstockblog.com/immunogen-at-ash-2007-%e2%80%93-part-ii-ave9633/#comment-489</guid>
		<description>IMGN and other drug companies should benefit from the aging baby boomer population.  If you have a 3-5 years timeframe, it's not a bad idea to load up on drug-related stocks.</description>
		<content:encoded><![CDATA[<p>IMGN and other drug companies should benefit from the aging baby boomer population.  If you have a 3-5 years timeframe, it&#8217;s not a bad idea to load up on drug-related stocks.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
